• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Pentosan Polysulfate Sodium Associated With Elevated Vision Impairment Reporting Signals

by
November 7, 2026
in Health
Reading Time: 2 mins read
0
Pentosan Polysulfate Sodium Associated With Elevated Vision Impairment Reporting Signals

Pentosan Polysulfate Sodium Associated With Elevated Vision Impairment Reporting Signals

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A real-world pharmacovigilance study assessing reports from the Food and Drug Administration Adverse Event Reporting System (FAERS) database indicates that pentosan polysulfate sodium (PPS) is associated with a significantly higher reporting frequency of vision impairment compared to other anticoagulants.

The study addressed recent concerns regarding the ocular safety of PPS and other anticoagulants, an area where comparative safety profiles have remained unclear. To clarify these relationships, researchers evaluated associations between specific anticoagulant medications—focusing particularly on PPS—and vision impairment using real-world adverse event data.

Investigators extracted reports from the FAERS database and conducted disproportionality analysis utilizing reporting odds ratios (ROR) to detect ocular safety signals. The research methodology also incorporated subgroup analysis, time-to-onset (TTO) analysis, co-medication analysis, and a global assessment of the evidence to describe the observed associations.

In the disproportionality analysis, PPS demonstrated significantly higher ROR values for vision impairment across all evaluated comparators (all p < 0.0001). Specifically, PPS showed an ROR of 149.25 (95% CI 127.61–174.57) compared to heparin, 161.49 (95% CI 137.95–189.04) compared to low molecular weight heparins (LMWHs), 181.96 (95% CI 134.54–246.09) compared to fondaparinux, and 126.68 (95% CI 113.93–140.85) compared to warfarin. Furthermore, PPS exhibited an ROR of 74.40 (95% CI 70.70–78.30) against direct oral anticoagulants (DOACs), 499.40 (95% CI 187.20–1332.27) against bivalirudin, and 18.66 (95% CI 9.25–37.64) against other glycosaminoglycan (GAG) analogues.

Time-to-onset analysis showed that PPS-associated vision impairment followed a random failure pattern, with males and younger patients experiencing earlier onset. Co-medication assessments detected no significant drug-drug interactions between PPS and commonly co-prescribed therapies. The authors noted that PPS may be associated with a higher frequency of reported vision impairment relative to other anticoagulants, underscoring the need for drug-specific safety monitoring and prospective studies to further elucidate anticoagulant ocular safety.

Subject of Research: Anticoagulant safety and vision impairment pharmacovigilance

Article Title: A comprehensive pharmacovigilance study of vision impairment associated with anticoagulants: disproportionality analysis and detection of potential drug-drug interaction signals

Article References: Huang, S., Feng, Y., Huang, Z., Zhou, Y., Liu, H., Chen, J., & Chen, Z. (2026). A comprehensive pharmacovigilance study of vision impairment associated with anticoagulants: disproportionality analysis and detection of potential drug-drug interaction signals. BMC Ophthalmology. https://doi.org/10.1186/s12886-026-05500-6

Image Credits: AI Generated

DOI: 10.1186/s12886-026-05500-6

Keywords: pharmacovigilance, pentosan polysulfate sodium, anticoagulants, vision impairment, FAERS, adverse drug events, drug safety, ocular safety, comprehensive, vision, impairment, associated

News Source: Ophelia Keating. (November 7, 2026). Pentosan Polysulfate Sodium Associated With Elevated Vision Impairment Reporting Signals. Scienmag.

Tags: adverse drug eventsanticoagulantsassociatedcomprehensivedrug safetyFAERSimpairmentocular safetypentosan polysulfate sodiumPharmacovigilancevisionvision impairment
Share12Tweet7Share2ShareShareShare1

Related Posts

Irish Primary Care Fourteen-Day Helicobacter Pylori Treatments Rose Twenty-Eight Percent Annually

Irish Primary Care Fourteen-Day Helicobacter Pylori Treatments Rose Twenty-Eight Percent Annually

November 17, 2026
Madagascar Prison Inmates Accepted COVID-19 Vaccination as an Individual Health Choice

Madagascar Prison Inmates Accepted COVID-19 Vaccination as an Individual Health Choice

November 17, 2026

Cardiac Protein MYBPHL Rises to Protect Against Bacterial Sepsis Myocardial Injury

November 17, 2026

Community-Based Wheelchair Skills Training Shows Potential Cost-Effectiveness in Irish Study

November 17, 2026

POPULAR NEWS

  • Endometrial Receptivity During Embryo Implantation Linked to Endoplasmic Reticulum Stress

    Endometrial Receptivity During Embryo Implantation Linked to Endoplasmic Reticulum Stress

    29 shares
    Share 12 Tweet 7
  • Floral and Genetic Traits Differentiate Dwarf Succulent Species in South Africa

    29 shares
    Share 12 Tweet 7
  • Protocol Outlines Precise Chromosomal DNA Manipulations in Plants Using Programmable Recombinases

    29 shares
    Share 12 Tweet 7
  • Mild Respiratory Viruses Do Not Accelerate Biological Immune Aging After Recovery

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Irish Primary Care Fourteen-Day Helicobacter Pylori Treatments Rose Twenty-Eight Percent Annually

Madagascar Prison Inmates Accepted COVID-19 Vaccination as an Individual Health Choice

Small Molecules Activate Telomerase and Attenuate Senescence Stress in Human Fibroblasts

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.